Cousins Properties Incorporated (CUZ) grew with the stock adding 0.12% or $0.01 to close at $8.6 on active trading volume of 3.28M compared its three months average trading volume of 3.02M. The Atlanta Georgia 30303 based company operating under the REIT – Diversified industry has been trending up for the last 52 weeks, with the shares price now 45.22% up for the period and up by 1.79% so far this year. With price target of $8.5 and a 54.4% rebound from 52-week low, Cousins Properties Incorporated has plenty of upside potential, making it a hold with a view buy.
Cousins Properties Incorporated, a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, as well as performs certain real estate-related services in the United States. The company operates through four divisions: Office/Multi-Family, Retail, Industrial, and Land. The Office/Multi-Family division develops and manages office projects primarily in Austin, Dallas, Charlotte, Birmingham, and Atlanta; develops and sells multi-family projects in urban locations in the southeastern United States; and manages and leases office properties owned by third parties. It also develops mixed use projects that contain multiple product types in communities where individuals live, work, and seek entertainment. As of December 31, 2006, this division owned interests in 20 operating office properties; and had 5 office or multi-family projects under development or redevelopment. The Retail division develops and manages retail shopping centers principally in Georgia, Tennessee, North Carolina, Texas, and Florida. As of the above date, this division owned 10 operating retail properties; and had 3 projects and 1 expansion under development. The Industrial division develops institutional warehouse and distribution properties in the metropolitan Atlanta area and the Dallas market. As of December 31, 2006, this division owned one operating industrial property and three projects under development. The Land division engages in the acquisition and entitlement of land, the development and sale of residential lots, and the acquisition and sale of certain undeveloped tracts of land to third parties. As of the above date, this division had 24 residential communities under development. The company qualifies as a REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. Cousins Properties was founded in 1958 and is based in Atlanta, Georgia.
Nuance Communications, Inc. (NUAN) gained $0.2 to close the day at a new closing price of $17.11, a 1.18% increase in value from its previous closing price that moved the stock 27.31% above its 52 week low of $13.44. A total of 3.28M shares exchanged hands during the day compared with its three month average trading volume of 3.5M. The stock, which fluctuated between $16.85 and $17.25 during the day, currently situated -16.78% below its 52 week high. The stock is up by 9.89% in the past one month and up by 18.98% over the past three months. With a one year target estimate of $20.89 and RSI of 73.81, the stock still has upside potential, making it a sell for now.
Nuance Communications, Inc. provides voice recognition and natural language understanding solutions worldwide. It operates through four segments: Healthcare, Mobile, Enterprise, and Imaging. The Healthcare segment offers transcription solutions, which enables physicians to streamline clinical documentation with medical transcription platform; Dragon Medical, a dictation software that empowers physicians to accurately capture and document patient care in real-time on various devices; clinical document improvement and coding solutions to ensure patient health information is accurately documented, coded, and evaluated; and diagnostic solutions that allows radiologists to document, collaborate, and share medical images and reports. It also provides Dragon professional and personal productivity solutions to business users and consumers. The Mobile segment provides a portfolio of virtual assistants and connected services built on voice recognition, text-to-speech, natural language understanding, dialog, and text input technologies to automotive manufacturers, device makers, and mobile operators. The Enterprise segment offers OnPremise solutions and services, an automated customer service solution comprising speech recognition, voice biometrics, transcription, text-to-speech, and dialog and analytics products; and OnDemand multichannel cloud, a platform that offers enterprises the ability to implement automatic customer service. The Imaging segment provides MFP Scan automation solutions to offer scanning and document management solutions; MFP Print automation solutions to deliver printing and document management solutions; and PDF and OCR software, a technology that enables the capture, creation, and management of document workflows. The company was formerly known as ScanSoft, Inc. and changed its name to Nuance Communications, Inc. in October 2005. Nuance Communications, Inc. was founded in 1992 and is headquartered in Burlington, Massachusetts.
Opko Health, Inc. (OPK) shares were up in last trading by 2.49% to $8.66. It experienced lighter than average volume on day. The stock increased in value by almost 5.35% over the past week and fell -3.02% in the past month. It is currently trading -11.4% below its 50 day moving average and -12.23% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -28.72% decrease in value from its one year high of $12.15. The RSI indicator value of 42.86, lead us to believe that it is a hold for now.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States, Ireland, Chile, Spain, Israel, and Mexico. Its diagnostics business operates Bio-Reference Laboratories, a clinical laboratory that offers comprehensive laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units. The Bio-Reference Laboratories also provides core genetic testing and leverages products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s pharmaceutical segment features Rayaldee, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency and VARUBI for chemotherapy-induced nausea and vomiting. Its biologics business engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product under development for the treatment of growth hormone deficiency, and developing Factor VIIa drug for hemophilia using the carboxl terminal peptide technology. The company was incorporated in 1991 and is headquartered in Miami, Florida.